The Financial Express15h
FDA gives nod to first rapid-acting insulin biosimilar for diabetes treatment
The U.S. Food and Drug Administration (USFDA) on Friday approved Merilog as biosimilar to Novolog (insulin aspart) for the ...
FDA approves first rapid-acting insulin
According to the FDA, the medication quickly helps to lower mealtime blood sugar spikes to improve control of blood sugar in ...
MedPage Today1d
FDA OKs First Rapid-Acting Insulin Biosimilar for Diabetes
The FDA approved insulin-aspart-szjj (Merilog) as the first rapid-acting insulin biosimilar product to treat adults and ...
Healio1d
FDA approves subcutaneous Merilog for glycemic control in diabetes
The FDA has approved the first rapid-acting biosimilar insulin product for glycemic control in people with diabetes. Merilog ...
Sanofi gets FDA approval for NovoLog insulin biosimilar
Sanofi (NASDAQ:SNY) has received FDA approval for Merilog, a biosimilar of Novo Nordisk's (NVO) rapid-acting insulin product NovoLog, for the improvement of glycemic control in adults and children ...
FDA approves Sanofi biosimilar product for treatment of diabetes
The U.S. Food and Drug Administration approved Merilog as biosimilar to Novolog for the improvement of glycemic control in adults and pediatric ...
FDA Approves First Rapid-Acting Insulin Biosimilar Product for Treatment of Diabetes
Today, the U.S. Food and Drug Administration approved Merilog (insulin-aspart-szjj) as biosimilar to Novolog (insulin aspart) for the improvement of glycemic control in adults and pediatric patients ...
drugdeliverybusiness1d
Insulet Omnipod 5 produces positive study outcomes in type 2 population
JAMA today published outcomes from a study evaluating the safety and efficacy of the Insulet Omnipod 5 in adults with type 2 ...
Does Medicare Cover Ozempic?
Over 40% of U.S. adults meet the medical classification for obesity, according to the Centers for Disease Control and ...
Healio1d
Automated insulin delivery lowers HbA1c, improves time in range in type 2 diabetes
Adults with insulin-treated type 2 diabetes had a significant HbA1c decline at 13 weeks with use of the Omnipod 5 automated ...
Remote Patient Monitoring Market to Hit USD 56.94 Billion by 2030 with 12.7% CAGR | MarketsandMarkets
The global remote patient monitoring market, valued at US$24.39 billion in 2023, is forecasted to grow at a robust CAGR of 12.7%, reaching US$27.72 ...